<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000391.v1.p1" parentStudy="phs000391.v1.p1" createDate="2011-08-04" modDate="2012-11-15">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Alan Shuldiner, MD</td><td>University of Maryland Baltimore, Baltimore, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>U01GM074518</td><td>National Institute of General Medical Sciences, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study</StudyNameEntrez>
	<StudyNameReportPage>Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Interventional</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>CHD is the leading cause of death in the United States. One of the most common ways to prevent CHD is to take an anti-platelet agent,      which lessens platelet aggregation. Two of the most common anti-platelet agents are aspirin and clopidogrel. However, up to 25% to 30%      of people do not respond to these medications. Evidence indicates that treatment response may be related to genetics. The purpose of      this study is to determine specific gene variants that predict response to aspirin and clopidogrel therapy.</p>     <p>This study is part of a larger group of studies called the Pharmacogenomics Research Network (PGRN). Participants are from the      Old Order Amish of Lancaster, Pennsylvania. They are well suited for genetic studies because they are a homogenous, closed, founder      population. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On      the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function      tests before and after clopidogrel alone, and then again after taking clopidogrel plus aspirin. Using the gene variation profiles      across the genome, researchers analyzed which variants correspond to treatment response.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Inclusion Criteria:       <ul>         <li>Of Old Order Amish descent</li>         <li>At least 20 years old</li>       </ul>     </p>     <p>Exclusion Criteria:       <ul>         <li>Currently pregnant or less than 6 months have passed since delivery</li>         <li>History of a bleeding disorder or major spontaneous bleed, such as peptic ulcer, epistasis, or intracranial bleed</li>         <li>Severe hypertension, defined by a blood pressure above 160/95 mm Hg, making it unethical not to recommend prompt treatment</li>         <li>Medications that would affect the outcome(s) to be measured and cannot willingly and safely, in the opinion of the treating          physician and study physician, discontinue these medications for 1 week prior to protocol initiation</li>         <li>Vitamins or other supplements and is unwilling to discontinue their use for at least 1 week prior to study</li>         <li>Coexisting malignancy</li>         <li>Creatinine level greater than 2.0 mg/dl, aspartate transaminase (AST) or alanine transaminase (ALT) greater than two times the          upper limit of normal, hematocrit less than 32%, or a thyroid-stimulating hormone (TSH) less than 0.4 or greater than 5.5 mIU/L</li>         <li>Bleeding disorder or history of gastrointestinal bleeding or other major bleeding episode</li>         <li>Currently taking aspirin, clopidogrel, or other anti-coagulant, such as warfarin, heparin, or GPIIb/IIIa antagonists, and have          conditions that might place them at increased risk from withdrawal of these medications 14 days prior to protocol initiation, including          history of unstable angina, heart attack, angioplasty (including stent placement), coronary artery bypass surgery, atrial fibrillation, stroke or transient ischemic attacks, diabetes, or deep vein thrombosis or other thrombosis</li>         <li>Polycythemia, or thrombocytosis, defined by a platelet count greater than 500,000</li>         <li>Thrombocytopenia, defined by a platelet count less than 75,000</li>         <li>Surgery within the last 6 months</li>         <li>Aspirin or clopidogrel allergy</li>         <li>Currently breast feeding</li>       </ul>     </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="19706858"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Pharmacogenomics"/>
		<Disease vocab_source="MESH" vocab_term="Clopidogrel"/>
		<Disease vocab_source="MESH" vocab_term="Platelets"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Alan Shuldiner, MD</AttName>
			<Institution>University of Maryland Baltimore, Baltimore, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01GM074518</AttName>
			<Institution>National Institute of General Medical Sciences, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="PAPI" url="http://medschool.umaryland.edu/Departments/Department-of-Medicine/Division-of-Endocrinology,-Diabetes-and-Nutrition/Amish-Studies/Pharmacogenomics-of-Anti-Platelet-Intervention-%28PAPI%29.asp"/>
	</StudyURLs>
	<StudyHistory><![CDATA[
<p>The PAPI Study began in August 2006.  Old Order Amish in Lancaster County who had participated in Dr. Shuldiner&#39;s HAPI Heart Study      were recruited.  Recruitment was liberalized to include family members of HAPI Heart participants.  In 2008 we completed the first      genome-wide association study (GWAS) of clopidogrel response in the first 420 PAPI Study participants. This work was published in      JAMA on August 25, 2009. Recruitment of the entire cohort, 676 individuals was completed in August 2010. GWAS genotyping (Affymetrics 6.0)      was completed in the fall 2010. After data cleaning, we completed our first pass GWAS in February 2011.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHLBI</DacName>
      <DacFullName>National Heart, Lung, and Blood Institute DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000391.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000391.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000391.v1.p1" FileName="PAPIDUC_April_2011.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>The informed consent document signed by the PAPI Study Participants allows use of these data by co-investigators in the Pharmacogenomics Research Network and other scientists with interest in CVD or related areas. This consent group does not require IRB approval.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>
  <Documents>
    <Document phd="phd003629.1" type="protocol" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003629.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3629">
      <OrigName>Article 19706858 Supplements.pdf</OrigName>
      <DisplayName>JAMA Article Supplements</DisplayName>
      <Description>JAMA Article Supplements</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003630.1" type="protocol" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003630.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3630">
      <OrigName>Article 19706858.pdf</OrigName>
      <DisplayName>Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy</DisplayName>
      <Description>Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003631.1" type="protocol" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003631.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3631">
      <OrigName>Clinic SOPs.pdf</OrigName>
      <DisplayName>Clinic SOPs</DisplayName>
      <Description>Clinic SOPs</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003632.1" type="consent-form" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003632.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3632">
      <OrigName>PAPI Consent.pdf</OrigName>
      <DisplayName>Research Consent Form</DisplayName>
      <Description>Research Consent Form</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003633.1" type="protocol" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003633.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3633">
      <OrigName>PAPI protocol.pdf</OrigName>
      <DisplayName>Research Plan</DisplayName>
      <Description>Research Plan</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003634.1" type="questionnaire" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003634.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3634">
      <OrigName>PAPI_Flow_Sheet_Clinic_I.pdf</OrigName>
      <DisplayName>PAPI Flow Sheet for Clinic Visit I</DisplayName>
      <Description>PAPI Flow Sheet for Clinic Visit I</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003635.1" type="coding-manual" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003635.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3635">
      <OrigName>PAPI_Flow_Sheet_Clinic_I_DD.pdf</OrigName>
      <DisplayName>PAPI Flow Sheet for Clinic Visit I - Data Dictionary</DisplayName>
      <Description>PAPI Flow Sheet for Clinic Visit I - Data Dictionary</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003636.1" type="questionnaire" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003636.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3636">
      <OrigName>PAPI_Flow_Sheet_Clinic_II.pdf</OrigName>
      <DisplayName>PAPI Flow Sheet for Clinic Visit II</DisplayName>
      <Description>PAPI Flow Sheet for Clinic Visit II</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003637.1" type="coding-manual" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003637.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3637">
      <OrigName>PAPI_Flow_Sheet_Clinic_II_DD.pdf</OrigName>
      <DisplayName>PAPI Flow Sheet for Clinic Visit II - Data Dictionary</DisplayName>
      <Description>PAPI Flow Sheet for Clinic Visit II - Data Dictionary</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003638.1" type="questionnaire" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003638.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3638">
      <OrigName>PAPI_Inclusion_Exclusion.pdf</OrigName>
      <DisplayName>PAPI Inclusion / Exclusion Criteria for Each Intervention</DisplayName>
      <Description>PAPI Inclusion / Exclusion Criteria for Each Intervention</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003639.1" type="coding-manual" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003639.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3639">
      <OrigName>PAPI_Inclusion_Exclusion_DD.pdf</OrigName>
      <DisplayName>PAPI Inclusion / Exclusion Criteria - Data Dictionary</DisplayName>
      <Description>PAPI Inclusion / Exclusion Criteria - Data Dictionary</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003640.1" type="questionnaire" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003640.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3640">
      <OrigName>PAPI_Lifestyle.pdf</OrigName>
      <DisplayName>PAPI Lifestyle</DisplayName>
      <Description>PAPI Lifestyle</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003641.1" type="coding-manual" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003641.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3641">
      <OrigName>PAPI_Lifestyle_DD.pdf</OrigName>
      <DisplayName>PAPI Lifestyle - Data Dictionary</DisplayName>
      <Description>PAPI Lifestyle - Data Dictionary</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003642.1" type="questionnaire" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003642.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3642">
      <OrigName>PAPI_Medical_History.pdf</OrigName>
      <DisplayName>PAPI Medical History</DisplayName>
      <Description>PAPI Medical History</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003643.1" type="coding-manual" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003643.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3643">
      <OrigName>PAPI_Medical_History_DD.pdf</OrigName>
      <DisplayName>PAPI Medical History - Data Dictionary</DisplayName>
      <Description>PAPI Medical History - Data Dictionary</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003644.1" type="questionnaire" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003644.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3644">
      <OrigName>PAPI_Medications.pdf</OrigName>
      <DisplayName>PAPI Medications</DisplayName>
      <Description>PAPI Medications</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003645.1" type="coding-manual" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003645.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3645">
      <OrigName>PAPI_Medications_DD.pdf</OrigName>
      <DisplayName>PAPI Medications - Data Dictionary</DisplayName>
      <Description>PAPI Medications - Data Dictionary</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003646.1" type="protocol" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003646.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3646">
      <OrigName>Table of Phenotypes.doc</OrigName>
      <DisplayName>Table of Phenotypes</DisplayName>
      <Description>Table of Phenotypes</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003647.1" type="protocol" createDate="2011-08-04" modDate="2012-11-15" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003647.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000391.v1.p1&amp;phd=3647">
      <OrigName>Institutional Approval dbGAP Shuldiner PAPI HP-43419.pdf</OrigName>
      <DisplayName>Institutional Approval</DisplayName>
      <Description>Institutional Approval</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
  </Documents>

  <Annotations>
    <DocumentPart phd="phd003632.1" sectionId="sec1">
      <phvList>
        <phvRef variableId="173920"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="g4">
      <phvList>
        <phvRef variableId="173934"/>
        <phvRef variableId="173935"/>
        <phvRef variableId="173936"/>
        <phvRef variableId="173937"/>
        <phvRef variableId="173938"/>
        <phvRef variableId="173939"/>
        <phvRef variableId="173940"/>
        <phvRef variableId="173941"/>
        <phvRef variableId="173942"/>
        <phvRef variableId="173943"/>
        <phvRef variableId="173944"/>
        <phvRef variableId="173945"/>
        <phvRef variableId="173946"/>
        <phvRef variableId="173947"/>
        <phvRef variableId="173948"/>
        <phvRef variableId="173949"/>
        <phvRef variableId="173950"/>
        <phvRef variableId="173951"/>
        <phvRef variableId="173952"/>
        <phvRef variableId="173953"/>
        <phvRef variableId="173954"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="g6">
      <phvList>
        <phvRef variableId="173934"/>
        <phvRef variableId="173935"/>
        <phvRef variableId="173936"/>
        <phvRef variableId="173937"/>
        <phvRef variableId="173938"/>
        <phvRef variableId="173939"/>
        <phvRef variableId="173940"/>
        <phvRef variableId="173941"/>
        <phvRef variableId="173942"/>
        <phvRef variableId="173943"/>
        <phvRef variableId="173944"/>
        <phvRef variableId="173945"/>
        <phvRef variableId="173946"/>
        <phvRef variableId="173947"/>
        <phvRef variableId="173948"/>
        <phvRef variableId="173949"/>
        <phvRef variableId="173950"/>
        <phvRef variableId="173951"/>
        <phvRef variableId="173952"/>
        <phvRef variableId="173953"/>
        <phvRef variableId="173954"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="li1">
      <phvList>
        <phvRef variableId="173930"/>
        <phvRef variableId="173931"/>
        <phvRef variableId="173932"/>
        <phvRef variableId="173933"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="sec28">
      <phvList>
        <phvRef variableId="173934"/>
        <phvRef variableId="173935"/>
        <phvRef variableId="173936"/>
        <phvRef variableId="173937"/>
        <phvRef variableId="173938"/>
        <phvRef variableId="173939"/>
        <phvRef variableId="173940"/>
        <phvRef variableId="173941"/>
        <phvRef variableId="173942"/>
        <phvRef variableId="173943"/>
        <phvRef variableId="173944"/>
        <phvRef variableId="173945"/>
        <phvRef variableId="173946"/>
        <phvRef variableId="173947"/>
        <phvRef variableId="173948"/>
        <phvRef variableId="173949"/>
        <phvRef variableId="173950"/>
        <phvRef variableId="173951"/>
        <phvRef variableId="173952"/>
        <phvRef variableId="173953"/>
        <phvRef variableId="173954"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="sec29">
      <phvList>
        <phvRef variableId="173934"/>
        <phvRef variableId="173935"/>
        <phvRef variableId="173936"/>
        <phvRef variableId="173943"/>
        <phvRef variableId="173944"/>
        <phvRef variableId="173945"/>
        <phvRef variableId="173946"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="sec41">
      <phvList>
        <phvRef variableId="173937"/>
        <phvRef variableId="173938"/>
        <phvRef variableId="173939"/>
        <phvRef variableId="173940"/>
        <phvRef variableId="173941"/>
        <phvRef variableId="173942"/>
        <phvRef variableId="173947"/>
        <phvRef variableId="173948"/>
        <phvRef variableId="173949"/>
        <phvRef variableId="173950"/>
        <phvRef variableId="173951"/>
        <phvRef variableId="173952"/>
        <phvRef variableId="173953"/>
        <phvRef variableId="173954"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="sec9">
      <phvList>
        <phvRef variableId="173937"/>
        <phvRef variableId="173938"/>
        <phvRef variableId="173939"/>
        <phvRef variableId="173940"/>
        <phvRef variableId="173941"/>
        <phvRef variableId="173942"/>
        <phvRef variableId="173947"/>
        <phvRef variableId="173948"/>
        <phvRef variableId="173949"/>
        <phvRef variableId="173950"/>
        <phvRef variableId="173951"/>
        <phvRef variableId="173952"/>
        <phvRef variableId="173953"/>
        <phvRef variableId="173954"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td1">
      <phvList>
        <phvRef variableId="173924"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td10">
      <phvList>
        <phvRef variableId="173930"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td11">
      <phvList>
        <phvRef variableId="173934"/>
        <phvRef variableId="173935"/>
        <phvRef variableId="173936"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td12">
      <phvList>
        <phvRef variableId="173930"/>
        <phvRef variableId="173931"/>
        <phvRef variableId="173932"/>
        <phvRef variableId="173933"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td13">
      <phvList>
        <phvRef variableId="173937"/>
        <phvRef variableId="173938"/>
        <phvRef variableId="173939"/>
        <phvRef variableId="173947"/>
        <phvRef variableId="173948"/>
        <phvRef variableId="173949"/>
        <phvRef variableId="173950"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td14">
      <phvList>
        <phvRef variableId="173940"/>
        <phvRef variableId="173941"/>
        <phvRef variableId="173942"/>
        <phvRef variableId="173951"/>
        <phvRef variableId="173952"/>
        <phvRef variableId="173953"/>
        <phvRef variableId="173954"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td2">
      <phvList>
        <phvRef variableId="173926"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td3">
      <phvList>
        <phvRef variableId="173927"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td4">
      <phvList>
        <phvRef variableId="173928"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td5">
      <phvList>
        <phvRef variableId="173930"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td6">
      <phvList>
        <phvRef variableId="173930"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td7">
      <phvList>
        <phvRef variableId="173930"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td8">
      <phvList>
        <phvRef variableId="173930"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003633.1" sectionId="td9">
      <phvList>
        <phvRef variableId="173930"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003634.1" sectionId="V30">
      <phvList>
        <phvRef variableId="173927"/>
        <phvRef variableId="173928"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003634.1" sectionId="sec3">
      <phvList>
        <phvRef variableId="173926"/>
        <phvRef variableId="173929"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003642.1" sectionId="V4">
      <phvList>
        <phvRef variableId="173924"/>
      </phvList>
    </DocumentPart>
  </Annotations>


<Analyses>
	<Analysis pha="3556" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3557" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3558" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3559" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3560" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3561" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3562" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3563" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3564" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3565" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3566" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3567" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3568" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3569" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3570" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3571" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3572" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3573" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3574" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3575" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="3576" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description>These genome-wide association analyses of platelet aggregation phenotypes were conducted as part of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study.  Participants are from the Old Order Amish of Lancaster, Pennsylvania. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before (pre-clopidogrel/pre-aspirin) and after (post-clopidogrel/pre-aspirin) clopidogrel alone, and then again after taking clopidogrel plus aspirin (post-clopidogrel/post-aspirin). Participants were free of clinical cardiovascular disease, consented to use of their DNA for genetic research, and were successfully genotyped on the Affymetrix 500K or Affymetrix 6.0 genome-wide SNP array. Genotyping was conducted at the University of Maryland, Baltimore..</Description>
		<Method>Quantitative trait analysis</Method>
		<GtyPlatform probeNum="934940" snpBatchId="52074">
			<Vendor>Affy</Vendor>
			<VendorURL>http://www.ncbi.nlm.nih.gov/SNP/snp_viewBatch.cgi?sbid=52074</VendorURL>
			<Platform>Affy1M</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
</Analyses>

</Study>

</Studies>

</GaPExchange>
